ArticleEssays in biochemistry2025
From molecular logic to therapeutic modulation: advances in Ub/UBL signalling.
Article in Essays in biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Ubiquitin (Ub) and ubiquitin-like proteins (UBLs) are central regulators of cell signalling, with roles spanning proteasomal degradation, immune defence, DNA repair, autophagy, and the stress response. Their conserved β-grasp fold provides a remarkably versatile protein architecture that can be redeployed across diverse signalling pathways and modulated in disease contexts. Conjugation and removal through dedicated E1-E2-E3 and protease systems generate a rich regulatory code, further diversified by chain topology, hybrid architectures, and emerging non-canonical modifications. This special issue highlights recent advances in Ub and UBL biology, from specialised UBL pathways to host-pathogen interactions and non-protein conjugation events, as well as translational applications such as targeted protein degradation. Together, these reviews showcase the breadth, adaptability, and therapeutic potential of these small but powerful modifiers.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.